MET and non-small cell lung carcinoma: , and rearrangements (rearr) have been implicated in the development of aggressive NSCLC, including KRAS (mut), EGFR (mut), FGFR1 (amp), ALK (rearr), HER2 (mut), MET (amp), and many other rare alterations in BRAF, PIK3CA, AKT1, MEK1, NRAS, RET, RB1, and NTRK (Table 1) [2].